James Kihara - 26 Jun 2026 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Reporting relationship: PRINCIPAL ACCOUNTING OFFICER
Issuer ticker: ACAD
Reported as of: 26 Jun 2026
Net transaction value: -$297,912
SEC form: 4
Accepted by SEC: 29 Jun 2026, 18:00:05 UTC
Prior SEC filing: 27 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact

Key filing fact

James Kihara filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 29 Jun 2026.

Key facts

This page summarizes James Kihara's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 29 Jun 2026, 18:00.

Change

Previous filing in this sequence was filed on 27 May 2026.
Current net transaction value: -$297,912.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001816160 Primary reporting owner

Kihara James

Relationship: PRINCIPAL ACCOUNTING OFFICER
Address: C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO
Signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact
Signature date: 29 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACAD transaction

Common Stock

Sale

Transaction value: $297,912
Shares: -11,421
Change %: -47%
Price: $26.08
Shares after: 13,088
Date: 26 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 9, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.88 to $26.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.